The Application and Breakthrough of Mesenchymal Stem Cells in the Treatment of Diabetes

Abstract

Diabetes is a widespread chronic metabolic disorder that endangers human health because of its high incidence, prolonged progression, and the severity of its complications. Blood glucose levels can be effectively managed through traditional therapies, including insulin injections and oral hypoglycemic agents.Since conventional therapies are unable to restore damaged islets or prevent the ongoing deterioration of β-cell function, patients remain reliant on lifelong medication. Over the past few years, stem cell approaches—particularly those involving mesenchymal stem cells—have drawn increasing attention as a novel therapeutic option. Given their intrinsic abilities of self-renewal, multipotent differentiation, and immunomodulation, mesenchymal stem cells have been recognized as multifunctional candidates in diabetes therapy, since they are capable not only of enhancing islet activity and preserving as well as regenerating pancreatic β-cells, but also of orchestrating immune responses, improving insulin sensitivity, and attenuating chronic complications such as nephropathy and neuropathy; moreover, accumulating evidence from preclinical research and early clinical investigations further indicates that Mesenchymal stem cell (MSC) transplantation contributes to the re-establishment of glucose homeostasis while exerting sustained protective influences through paracrine signaling and anti-inflammatory cascades. However, challenges such as low differentiation efficiency, limited cell survival in vivo, and safety concerns remain to be addressed before large-scale clinical application can be realized. Overall, MSC-based therapy represents a novel and potentially transformative approach for diabetes treatment, offering hope for achieving functional recovery beyond symptomatic control.